New Diabetes Drug

2018-11-29 - 15:26 | News | Tags: , |

Exenatide once weekly now type 2 diabetes approved for people with type 2 diabetes is available from September 1st 2011 a new treatment option available: Exenatide once weekly (product name Bydureon ). It is the first and only antidiabetic, which is administered only once in a week. Thanks to an innovative technology, which includes the active ingredient in so-called Microsphere globules, Exenatide is released evenly. This can lead to a continuous effect and thus to a convincing blood sugar reduction with low Unterzuckerungsrisiko with good tolerability. In addition, the new drug can help weight obese patients. Cheap, risk factors such as blood pressure and blood fat values can be affected. The European health authority has approved the new drug of company Lilly in combination with oral antidiabetic drugs (metformin or sulfonylurea, metformin or Glitazone) if metformin alone is not enough. The prescription medicines was developed together with the company Amylin and Alkermes.

People with type 2 diabetes have mostly with other risk factors such as obesity or high blood pressure and blood fat values to fight. An early, strong glycemic control can improve the prognosis of for patients in the long term in terms of complications associated. 1 x weekly therapy is a great milestone in the treatment of people with type 2 diabetes and can make life with diabetes easier. As a result, physicians, diabetes consultants and patients targeted on their way to a joint treatment success are supported. 1 x weekly therapy is therefore particularly suitable for patients who are in the middle of the life and need a reliable therapy, just insert in your life can be, “explains Arnaud reading Gretain, Director diabetes of the Lilly Germany GmbH. new of GLP-1 receptor agonist for effective, Exenatide once a week is a new long effective representative in the therapeutic class GLP-1 receptor agonists. Different effects of human intestinal hormone mimics this substance class (= Incretin) to glucagon-like peptide-1 (GLP-1): the active ingredient of Exenatide in a short-acting form (twice daily injection) by the company Lilly 2007 as the first representative of this new class of drugs in Germany introduced belongs also the 2009 introduced substance Liraglutide (once-daily injection).